Drugs / TL-118
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06010342 | Mar 2023 → Dec 2027 expected | cancer | Teligene US | Recruiting | No outcome recorded |
| Phase 2 | NCT01659502 | Dec 2013 → Oct 2014 | malignant pancreatic neoplasm | Tiltan Pharma Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01509911 | Jan 2012 → Oct 2016 | malignant pancreatic neoplasm | Tiltan Pharma Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tl-118 | “A Clinical Trial of Anti-Angiogenic Drug Combination Tl-118 for Pancreatic Cancer Patients Who Are Starting Gemcitabine Treatment” NCT01509911 ↗ |
| Action | Inhibit | “TL118 is an orally active inhibitor of the tropomyosin receptor kinase (Trk) family consists of TrkA, TrkB, and TrkC.” NCT06010342 ↗ |
| Route | Oral | “supplied as an oral liquid for daily administration” NCT01509911 ↗ |